Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.
Richard M SilverD A WilsonT AkterI AtanelishviliJ T HugginsK KajdaszK B HighlandP J NietertG S BogatkevichPublished in: ACR open rheumatology (2019)
Dabigatran appears to be safe and well tolerated in patients with SSc-ILD. A larger randomized controlled trial to test the efficacy of direct thrombin inhibition with dabigatran can be considered.